VIVA and The VEINS 2024: Landmark Vascular and Venous Clinical Trial Data Unveiled
核心洞察
Twenty-one clinical trials in vascular and venous disease will be presented at VIVA and The VEINS conferences, showcasing advancements in treatment and intervention.
Studies include novel thrombectomy devices for pulmonary embolism (搜索) and two-year outcomes for drug-eluting scaffolds in infrapopliteal lesions.
Research spans from randomized controlled trials comparing surgical methods to registry data focused on underrepresented minorities in endovascular PAD treatment.
Leading physicians and researchers are set to present findings from 21 clinical trials at the annual VIVA (Vascular InterVentional Advances) and The VEINS (Venous Endovascular INterventional Strategies) conferences, scheduled from November 3-5 at Wynn Las Vegas. The data encompasses a range of vascular and venous disorders, offering insights into novel treatments and long-term outcomes.
Pulmonary Embolism and Thrombectomy
Dr. Julie Bulman will present data on clot burden reduction using a novel thrombectomy device for acute pulmonary embolism (搜索). The pilot ENGULF trial assessed the device's impact on RV/LV ratio and MMS reductions, key indicators of improved cardiac function and reduced clot burden.
Venous Stenting and Surgical Comparisons
Dr. Manj Gohel will present findings from a randomized controlled trial comparing cyanoacrylate closure to surgical stripping for venous disorders, focusing on secondary outcomes through six months within the Spectrum Program. Dr. Mahmood Razavi will share 24-month results from the VIVID trial, which investigated a venous stent system for iliofemoral vein (搜索) treatment.
Peripheral Artery Disease (PAD) Interventions
Several presentations will focus on advancements in treating peripheral artery disease (搜索). Dr. Brian DeRubertis will present two-year outcomes from the LIFE-BTK trial, evaluating the Esprit™ BTK (搜索) drug-eluting resorbable scaffold for infrapopliteal lesions. Dr. Venita Chandra will discuss 30-day outcomes from the Disrupt PAD BTK II study, which uses the Shockwave (搜索) intravascular lithotripsy system for calcified below-the-knee PAD.
Lithotripsy and Atherectomy Techniques
Additional studies will highlight lithotripsy techniques, with Dr. Thomas Zeller presenting results from the RESTORE ATK and RESTORE BTK trials, which assessed a laser and optics-based peripheral intravascular lithotripsy system for above-the-knee and below-the-knee calcified lesions. Dr. John Corl will discuss the first clinical use of a forward-shifted peripheral intravascular lithotripsy system, presenting late-breaking primary outcomes from the Mini S/FORWARD PAD IDE study. Dr. Venita Chandra will also present a comparison of directional atherectomy versus balloon predilatation prior to drug-coated balloon treatment of long, calcified femoropopliteal lesions in the TOTAL REALITY trial.
Carotid Artery Revascularization and Stenting
Dr. Meghan Dermody will present 30-day outcomes from the ROADSTER 3 study, a prospective, multicenter evaluation of transcarotid artery revascularization in standard-risk patients. Dr. William A. Gray will share two-year outcomes from the PERFORMANCE II trial, investigating a 3-in-1 carotid stent system with integrated embolic protection.
Deep Vein Thrombosis and Healthcare Resource Utilization
Dr. David J. Dexter will present complete two-year outcomes in patients receiving mechanical thrombectomy for deep vein thrombosis (搜索) in the CLOUT Registry. Dr. Parag J. Patel will discuss healthcare resource utilization and outcomes among patients with intermediate-risk pulmonary embolism (搜索) treated with computer-assisted vacuum thrombectomy versus other treatment modalities.
Paclitaxel-Coated Balloons and Sirolimus-Coated Balloon Angioplasty
Dr. Ulf Teichgräber will present a post hoc analysis of the randomized SIRONA trial, comparing sirolimus-coated balloon angioplasty to various paclitaxel-coated balloon types.
Diversity and Inclusion in PAD Treatment
Dr. Lee Kirksey will present 12-month clinical results from the first 500 patients in the ELEGANCE Registry, focusing on endovascular PAD treatment with drug-eluting devices in underrepresented minorities and women.